The topic of the “new European limit” for plant extracts is generating considerable discussion, particularly when it comes to hemp, CBD, THC, and products sold online. In practice, it's crucial to clarify one key point immediately: the cited European sources do not contain a single, general limit applicable to all plant extracts. The European Union primarily regulates specific categories of products based on their use, composition, and method of marketing.
For consumers and professionals alike, the impact is very real. Between the proposed reform of the Common Agricultural Policy (CAP), which sets a 0.3% Δ9-THC threshold for raw Cannabis sativa L., the already established maximum levels for certain hemp-based foods, the increased monitoring of medicines sold online, and heightened vigilance surrounding more potent extracts, the market is evolving rapidly. Here's what this means in concrete terms for online commerce, medicine, and roadside checks.
A European limit, but above all sectoral rules
When discussing new European limits for plant extracts, it's important to avoid oversimplification. Recent legislation primarily outlines distinct rules depending on the product: agricultural hemp, food products, medicines, or products marketed as wellness solutions. In other words, EU law doesn't treat all plant extracts as a single, homogenous category.
The most discussed benchmark concerns raw hemp. In the proposed reform of the CAP for 2025, Cannabis sativa L. hemp is specified with a maximum Δ9-THC content not exceeding 0.3%. This threshold plays a structuring role for the sector, as it influences agricultural production, varietal selection, and, indirectly, the supply to legal CBD producers
A 2026 text further stipulates that member states must conduct at least 15% on-site inspections of hemp production. This demonstrates a clear direction: Europe is no longer content with simply setting thresholds; it is also strengthening concrete on-the-ground verification. For the market, this means greater traceability, more analysis, and less room for guesswork.
What the 0.3% threshold changes for the hemp and CBD sector
The 0.3% THC threshold for raw hemp is not merely a technical detail for farmers. It has cascading repercussions throughout the entire supply chain, from cultivation to final sale. Producers must ensure their varieties, cultivation methods, and analyses remain compliant with regulations.
For online CBD shops, this means an even greater need to work with reputable suppliers who can provide consistent lab results and clear documentation. In a market where customers want both attractive prices and reliable products, compliance becomes as important a selling point as sensory quality or fast delivery.
This evolution could also strengthen the differentiation between sellers. Well-organized players, who focus on tested batches, transparent product information, and clean sourcing, should emerge as winners. Conversely, opaque or opportunistic operators are more likely to disappear under the pressure of controls, logistical restrictions, and growing consumer distrust.
Hemp-based foods: maximum limits already regulated since 2022
Another often-confused point concerns hemp-based food products. Since Regulation (EU) 2022/1393, maximum Δ9-THC levels have already been set for hemp seeds and certain derived products. Here again, we are not dealing with a universal rule for all plant extracts, but rather with targeted regulations depending on the nature of the food.
This framework is of major practical importance for hemp-based edible oils, ingredients, snacks, and other products. It serves to protect consumers while harmonizing the European market. The regulation also includes transitional provisions for products already legally placed on the market before January 1, 2023, which allowed for a smoother transition without abruptly disrupting existing supply.
For e-commerce businesses, this means clearly distinguishing between product categories and the claims they make. An item sold as food is not subject to the same logic as a product presented as therapeutic or a technical raw material. This distinction is essential to avoid errors in marketing, communication, and labeling.
Online marketplace: towards stricter screening of authorized sellers
One of the most visible impacts of this regulatory pressure concerns the online market. The European Union reminds authorized pharmacies and online retailers that when selling medicines, they must display the common European logo and be listed in national registers. This point becomes crucial as soon as a plant extract is presented as a health product.
Meanwhile, the EMA and the heads of national agencies are reporting a sharp increase in illegal medicines sold online in the EU. This "sharp rise" is alerting authorities to parallel distribution channels, misleading therapeutic claims, and insufficiently controlled products. In this environment, plant extracts are no exception, especially when they are presented with quasi-medical rhetoric.
For the buyer, the right approach is simple: check the seller's authorization in national registers when it comes to health products, and favor shops that are transparent about origin, testing, and compliance. For reputable retailers, it's also an opportunity. The more rigorous the vetting of authorized sellers becomes, the more trust can be placed in those who are clearly playing by the rules.
Medicine: the line remains clear between wellness products and medication
European authorities maintain a very clear distinction between authorized health products and those that have not been evaluated. A plant extract, even a popular or natural one, does not automatically become a recognized medicine. To be marketed as such in the EU, it must undergo rigorous evaluations of its quality, safety, and efficacy.
The EMA rightly points out that medicines purchased online outside of authorized channels may not have undergone these controls. This exposes patients to obvious risks: inaccurate composition, inconsistent dosage, contaminants, poorly documented interactions, or unfounded clinical claims. In the case of cannabis extracts, this caution is even more critical as concentrations increase.
For healthcare professionals, this evolution requires more education. Patients hear about hemp, CBD, full-spectrum extracts, or new cannabinoids, but these products do not all have the same status. The right approach is to distinguish between legally sold wellness products, supplements or foods that may be subject to regulations, and medications, which fall under a different level of regulatory requirements.
More potent extracts: why health vigilance is increasing
The regulatory trend for 2026 is also driven by the rise of more concentrated products. EUDA indicates that cannabis, including extracts and high-potency edibles, has been linked to hospital emergency room visits in Europe. While not all extracts pose the same risks, this information inevitably changes how authorities view the market.
In practical terms, the more concentrated a product is, the more critical issues of dosage, responsible use, and consumer information become. This doesn't just apply to illicit products: even in a legal sales environment, transparency regarding composition and cannabinoid content is essential to minimize unpleasant surprises and inappropriate use.
This health-related pressure could lead to a gradual tightening of documentary, analytical, and commercial controls. Sellers offering reputable plant extracts therefore have every incentive to anticipate this: accurate product descriptions, accessible certificates of analysis, communication free of misleading medical claims, and robust traceability. This is the best response to a market that is becoming more mature, but also more closely monitored.
Roadside checks: the real issue remains the presence of THC
On the road, the central question isn't whether the product consumed is "plant-based," natural, or derived from hemp. The main issue remains the detection of THC. If a plant extract contains THC, it can trigger a positive test, depending on national practices. The European texts consulted primarily focus regulations on THC content and agricultural controls, not on a roadside exception linked to the product's plant origin.
The impact of the new European dynamic is therefore primarily indirect. If the market sees more concentrated extracts circulating, or if monitoring uncovers mislabeled products, the likelihood of problematic situations mechanically increases. A consumer may believe they are buying a harmless product when its actual composition exposes them to a positive result during an inspection.
The message of caution is clear for consumers: check product analyses, avoid products of dubious origin, and don't confuse commercial legality with a complete absence of risk in terms of roadside checks. For law enforcement, market developments could also make checks more complex, particularly with products that resemble CBD but have higher cannabinoid profiles.
What consumers and sellers need to remember in 2026
For adult consumers in France and Europe, the best approach is to prioritize products that have been laboratory tested, are clearly described, and are sold by transparent companies. In a context where plant extracts attract both innovation and questionable practices, clarity becomes a crucial purchasing criterion. An attractive price remains appealing, but never at the expense of compliance and safety.
For online retailers, this is a strategic period. European regulations don't close the market; they primarily encourage greater professionalism. Accurate product display, up-to-date analyses, a clear distinction between wellness and health products, and verification of specific obligations based on the product category sold: these are now essential foundations for long-term success.
In summary, the new European limit for plant extracts should be understood as part of a broader movement toward regulatory clarification. Between the 0.3% threshold for raw hemp, the existing maximum limits for food products, the monitoring of illegal medicines online, and the focus on more potent extracts, Europe is sending a clear signal: more control, more scrutiny, and greater transparency requirements.
This movement could be excellent news for serious players in the hemp and CBD sectors. It fosters a more transparent market, where well-researched, legal, and well-presented products are more valuable. For both buyers and professionals, the objective remains the same: access to reliable, compliant products adapted to a rapidly developing European framework.
